<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659971</url>
  </required_header>
  <id_info>
    <org_study_id>PBC002-01</org_study_id>
    <nct_id>NCT00659971</nct_id>
  </id_info>
  <brief_title>Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis</brief_title>
  <official_title>A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacgen Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pacgen Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal dose of PAC113 mouthrinse for treatment&#xD;
      of oral candidiasis in HIV seropositive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, examiner-blinded, positive-controlled, parallel design clinical trial,&#xD;
      which features 4 treatment arms. Forty-five (45)* HIV positive subjects per treatment arm&#xD;
      will be recruited for 180 subjects total. The study includes 5 visits: a screening visit, a&#xD;
      14-day treatment phase with a baseline visit on Day 1, a Day 7 visit, a post-treatment visit&#xD;
      5 days after the last dose, and follow-up visit. During the screening visit subjects will be&#xD;
      assessed for study eligibility. Eligible subjects will be randomized to 1 of the following&#xD;
      treatment arms:&#xD;
&#xD;
      A. 0.15% PAC-113 mouthrinse (5 mL 4 times daily [q.i.d.]); B. 0.075% PAC-113 mouthrinse (5 mL&#xD;
      q.i.d.); C. 0.0375% PAC-113 mouthrinse (5 mL q.i.d.); D. Nystatin oral suspension (100,000&#xD;
      units/mL; 5 mL q.i.d.) Subjects will be evaluated clinically for safety and severity of&#xD;
      clinical signs and symptoms of oral candidiasis at baseline (Day 1), Day 7, Day 19 (5 days&#xD;
      post-treatment) and Day 28 (follow-up visit). Subjects will also have a microbiological&#xD;
      analysis performed at screening, and at Days 7, 19 and 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eliminating or reducing clinical signs and symptoms of oral Candida infections.</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the microbiological response of Candida to different concentrations of PAC-113.</measure>
    <time_frame>Day 19</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Oral Candidiasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC113 0,15% mouthrinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC113 0,075% mouthrinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC113 0,0375% mouthrinse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nystatin suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC113</intervention_name>
    <description>PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are male or female 18 to 65 years of age, inclusive&#xD;
&#xD;
          -  Are able and willing to follow study procedures and instructions&#xD;
&#xD;
          -  Are able to read, understand and sign an informed consent form&#xD;
&#xD;
          -  Are documented as HIV positive&#xD;
&#xD;
          -  Have pseudomembranous and/or erythematous oral candidiasis as confirmed by potassium&#xD;
             hydroxide preparation of mucosal scraping&#xD;
&#xD;
          -  Have a CD4 cell count performed prior to randomization or within 6 weeks prior to the&#xD;
             screening visit&#xD;
&#xD;
          -  Have a viral load performed prior to randomization or within 6 weeks prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Both men and women who are active heterosexually must be willing to practice a&#xD;
             medically accepted method of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received systemic antifungal therapy within 14 days of starting study&#xD;
&#xD;
          -  Have received prior topical therapy for oral candidiasis within 7 days of starting&#xD;
             study&#xD;
&#xD;
          -  Have a concomitant fungal infection requiring systemic therapy&#xD;
&#xD;
          -  Are currently receiving immunosuppressive therapy (e.g. corticosteroids), or cancer&#xD;
             chemotherapy&#xD;
&#xD;
          -  Female subjects who are pregnant (as determined by a positive serum or urine pregnancy&#xD;
             test) or lactating, or female subjects who are of childbearing potential and who are&#xD;
             not using hormonal or barrier methods of birth control (e.g., oral or parenteral&#xD;
             contraceptives, diaphragm plus spermicide, condoms) or who have not characterized&#xD;
             themselves as abstinent. Subjects who use hormonal contraceptives must have started&#xD;
             the method at least 30 days prior to the screening examination&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Have esophageal symptoms (dysphagia or odynophagia) unless esophageal candidiasis has&#xD;
             been ruled out by endoscopy&#xD;
&#xD;
          -  Have a life expectancy &lt; 4 weeks&#xD;
&#xD;
          -  Are currently receiving or have received an investigational agent in the last 30 days&#xD;
&#xD;
          -  Have had a change in antiretroviral therapy within 14 days prior to study entry (this&#xD;
             does not apply to dose adjustment of the same therapy)&#xD;
&#xD;
          -  Have any of the following laboratory abnormalities:&#xD;
&#xD;
               -  White blood cell (WBC) count &lt;1,500 cells/mm3&#xD;
&#xD;
               -  Neutrophil granulocyte count &lt;1,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin &lt;9.0/dL&#xD;
&#xD;
               -  Transaminases (alanine aminotransferase [ALT] or aspartate aminotransferase&#xD;
                  [AST]) or bilirubin &gt;3 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum creatinine &gt;2 times ULN&#xD;
&#xD;
          -  Have peri-oral lesion (perleche) only&#xD;
&#xD;
          -  Have oral manifestations of herpes simplex (active disease only), hairy leukoplakia&#xD;
             and/or aphthous ulcers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rosedale Infectious Disease</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Pacgen Biopharmaceuticals Corp.</name_title>
    <organization>Director, Drug Development</organization>
  </responsible_party>
  <keyword>oral candidiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Candidiasis, Oral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

